Literature DB >> 21286941

Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer.

Giovanni de Manzoni1, Alberto Di Leo, Franco Roviello, Daniele Marrelli, Simone Giacopuzzi, Anna Maria Minicozzi, Giuseppe Verlato.   

Abstract

BACKGROUND: This study was designed to identify pathological predictors of para-aortic nodal invasion in advanced gastric cancer.
METHODS: Between 1990 and 2007, 294 patients with advanced gastric cancer underwent gastrectomy with D2 lymphadenectomy + para-aortic nodal dissection in Siena and Verona, Italy.
RESULTS: Forty-seven (16%) patients had para-aortic node metastases. Of these, 91%, 88%, and 74%, respectively, also had metastases at stations No. 3, No. 1, and No. 7. Para-aortic node metastases were never observed when stations No. 1 and No. 3 were both negative. Patients were divided into three groups, according to the risk of para-aortic node invasion: (1) high-risk group (n = 24, 8.2%), presenting a 42% risk and comprising T3/T4 cancers with mixed/nonintestinal histology, arising from the upper third; (2) low-risk group (n = 138, 46.9%), presenting a 0-10% risk and including middle-lower third tumors-either T2 irrespective of histology, or T3/T4 with intestinal histology; (3) intermediate-risk group, comprising all other patients (n = 132, 44.9%). Their risk ranged between 16% and 30%, but increased up to 21-37.5% after excluding 33 patients with negative No. 1 and No. 3 stations.
CONCLUSIONS: The combination of tumor site, histology, and T stage with perigastric nodal status allowed identification of patients at higher risk of para-aortic nodal invasion who could benefit from para-aortic nodal dissection.

Entities:  

Mesh:

Year:  2011        PMID: 21286941     DOI: 10.1245/s10434-010-1547-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  Lymphadenectomy: state of the art.

Authors:  Daniele Marrelli; Lorenzo De Franco; Livio Iudici; Karol Polom; Franco Roviello
Journal:  Transl Gastroenterol Hepatol       Date:  2017-01-17

Review 2.  Surgical anatomy of gastric lymphatic drainage.

Authors:  Maria Carmen Lirosi; Alberto Biondi; Riccardo Ricci
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-01

Review 3.  Clinical impact of molecular classifications in gastric cancer.

Authors:  Daniele Marrelli; Karol Polom; Alessandro Neri; Franco Roviello
Journal:  Updates Surg       Date:  2018-05-23

Review 4.  Multimodal treatment of gastric cancer in the west: Where are we going?

Authors:  Daniele Marrelli; Karol Polom; Giovanni de Manzoni; Paolo Morgagni; Gian Luca Baiocchi; Franco Roviello
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 5.  On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer.

Authors:  Roman Yarema; Giovanni de Manzoni; Taras Fetsych; Myron Ohorchak; Mykhailo Pliatsko; Maria Bencivenga
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

Review 6.  Gastric cancer: Current status of lymph node dissection.

Authors:  Maurizio Degiuli; Giovanni De Manzoni; Alberto Di Leo; Domenico D'Ugo; Erica Galasso; Daniele Marrelli; Roberto Petrioli; Karol Polom; Franco Roviello; Francesco Santullo; Mario Morino
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

7.  Is There Any Role for D3 Lymphadenectomy in Gastric Cancer?

Authors:  Gerassimos N Douridas; Stefanos K Pierrakakis
Journal:  Front Surg       Date:  2018-03-22

Review 8.  Current status of extended 'D2 plus' lymphadenectomy in advanced gastric cancer.

Authors:  Jing-Quan Li; Donglei He; Yue-Xiang Liang
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

Review 9.  Complete Mesogastric Excisions Involving Anatomically Based Concepts and Embryological-Based Surgeries: Current Knowledge and Future Challenges.

Authors:  Sergii Girnyi; Marcin Ekman; Luigi Marano; Franco Roviello; Karol Połom
Journal:  Curr Oncol       Date:  2021-11-22       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.